Moderna Reports Covid Vaccine Safe for Children 6 to 12
The pharmaceutical giant plans to submit its findings later this week to federal regulators
The pharmaceutical giant plans to submit its findings later this week to federal regulators
Today, the U.S. Food and Drug Administration took action to expand the use of a booster dose for COVID-19 vaccines in eligible populations.
As the COVID-19 pandemic lingers on with Black Californians still lagging behind on getting fully vaccinated, leaders in the state, including Gov. Newsom, are taking steps to push more people to get the shot. It is the most effective way, public health experts say, we will end the global public health crisis.
CDC Says All Vaccines Offer Strong Resistance to the Virus According to a new report from the Centers for Disease Control and Prevention, two-dose regimens of the Moderna and Pfizer-BioNTech mRNA vaccines provided a high level of protection against COVID-19 hospitalizations in a real-world evaluation at 21 U.S. hospitals during the period between March 11 and August 15. Vaccine effectiveness against COVID-19 hospitalization for Moderna and Pfizer-BioNTech doses were 93 percent and 88 percent, respectively, whereas the single-dose Janssen vaccine had a lower effectiveness rate at 71 percent. Protection for the Pfizer-BioNTech vaccine declined four months after
Once the vaccines arrive in California, they will be sent to hospitals and other facilities that can store them at around minus 94 degrees Fahrenheit.
Based on recently completed studies and epidemiologic data, the FDA has concluded that current policies regarding certain donor eligibility criteria can be modified without compromising the safety of the blood supply. Therefore, the FDA is revising recommendations in several guidances regarding blood donor eligibility. These changes are being put forth for immediate implementation and are expected to remain in place after the COVID-19 pandemic ends, with any appropriate changes based on comments we receive and our experience implementing the guidances. At this time, the alternatives to certain donor eligibility requirements being provided generally will apply only for the duration of the declared pandemic.
Most shortages involve low-profit generic pills and injections